B. A. Agnarsson, J. G. Jonasson, I. B. Björnsdottir, R. B. Barkardottir, V. Egilsson et al., Inherited BRCA2 mutation associated with high grade breast cancer, Breast Cancer Research and Treatment, vol.56, issue.Suppl, pp.121-148, 1998.
DOI : 10.1023/A:1005853022804

T. E. Alpert, G. Et-bruce, and . Haffty, Conservative Management of Breast Cancer in BRCA1/2 Mutation Carriers, Clinical Breast Cancer, vol.5, issue.1, pp.37-42, 2004.
DOI : 10.3816/CBC.2004.n.008

A. C. Antoniou, P. P. Pharoah, P. Smith, and D. F. Easton, The BOADICEA model of genetic susceptibility to breast and ovarian cancer, British Journal of Cancer, vol.88, issue.8, 2004.
DOI : 10.1038/sj.bjc.6602175

A. C. Antoniou, F. Durocher, P. Smith, J. Simard, and D. F. Easton, et INHERIT BRCAs program members. 2006. « BRCA1 and BRCA2 Mutation Predictions Using the BOADICEA and BRCAPRO Models and Penetrance Estimation in High-Risk French-Canadian Families », Breast Cancer Research: BCR, vol.8, issue.1, p.10, 1186.

A. Antoniou, P. D. Pharoah, S. Narod, H. A. Risch, J. E. Eyfjord et al., Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies, The American Journal of Human Genetics, vol.72, issue.5, pp.1117-1147, 2003.
DOI : 10.1086/375033

A. Ardern-jones, R. Kenen, and E. R. Eeles, Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40, European Journal of Cancer Care, vol.164, issue.3, 2005.
DOI : 10.1002/ijc.10641

J. E. Armes, A. J. Matthew-egan, M. C. Southey, G. S. Dite, M. R. Mccredie et al., « The Histologic Phenotypes of Breast Carcinoma Occurring before Age 40 Years in Women with and without BRCA1 or BRCA2 Germline Mutations », 11<2335::AID- CNCR13>3.0.CO, pp.10-1002, 1998.

A. L. Bane, J. C. Beck, I. Bleiweiss, S. S. Buys, E. Catalano et al., BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays, The American Journal of Surgical Pathology, vol.31, issue.1, 2007.
DOI : 10.1097/01.pas.0000213351.49767.0f

N. N. Basu, S. Ingham, J. Hodson, F. Lalloo, M. Bulman et al., « Risk of Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers: A 30- Year Semi-Prospective Analysis ». Familial Cancer, août, 2015.

J. Bernier and P. Poortmans, Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: A review, The Breast, vol.24, issue.2, 2015.
DOI : 10.1016/j.breast.2014.12.003

V. Bonadona, S. Dussart-moser, N. Voirin, O. M. Sinilnikova, H. Mignotte et al., Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review, Breast Cancer Research and Treatment, vol.22, issue.2, pp.233-278, 2006.
DOI : 10.1007/s10549-006-9288-7

URL : https://hal.archives-ouvertes.fr/hal-00434563

B. Bonaïti, F. Alarcon, V. Bonadona, S. Pennec, N. Andrieu et al., Catherine Bonaïti-Pellié, et Groupe Génétique et Cancer. 2011. « [A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition] », Bulletin Du Cancer, vol.98, issue.7, pp.779-95

C. Bonaiti-pellie, N. Andrieu, and . Avreux, « Oncogénétique: estimation des besoins en France pour les 10 ans à venir. Synthèse », Bulletin du Cancer, vol.96, pp.875-900, 2009.

J. C. Boughey, L. Tanya, L. C. Hoskin, J. L. Hartmann, S. R. Johnson et al., Impact of Reconstruction and Reoperation on Long-Term Patient-Reported Satisfaction After Contralateral Prophylactic Mastectomy, Impact of Reconstruction and Reoperation on Long-Term Patient-Reported Satisfaction after Contralateral Prophylactic Mastectomy, pp.401-409, 2015.
DOI : 10.1245/s10434-014-4053-3

C. T. Brekelmans, M. M. Tilanus-linthorst, C. Seynaeve, A. Vd-ouweland, M. B. Menke-pluymers et al., Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases, European Journal of Cancer, vol.43, issue.5, 1990.
DOI : 10.1016/j.ejca.2006.12.009

P. J. Bresser, C. Seynaeve, A. R. Van-gool, C. T. Brekelmans, H. Meijers-heijboer et al., Satisfaction with Prophylactic Mastectomy and Breast Reconstruction in Genetically Predisposed Women, Plastic and Reconstructive Surgery, vol.117, issue.6, 2006.
DOI : 10.1097/01.prs.0000217383.99038.f5

R. D. Chacón, V. Et-maría, and . Costanzo, Triple-negative breast cancer, Breast Cancer Research: BCR 12 Suppl, pp.10-1186, 2010.
DOI : 10.1073/pnas.0903392106

X. Chai, T. M. Friebel, C. F. Singer, D. Gareth-evans, H. T. Lynch et al., Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers, Breast Cancer Research and Treatment, vol.118, issue.2013, pp.397-406, 2014.
DOI : 10.1007/s10549-014-3134-0

A. Chung, K. Huynh, C. Lawrence, M. Sim, and A. Giuliano, Comparison of Patient Characteristics and Outcomes of Contralateral Prophylactic Mastectomy and Unilateral Total Mastectomy in Breast Cancer Patients, Annals of Surgical Oncology, vol.17, issue.Suppl 3, pp.2600-2606, 2012.
DOI : 10.1245/s10434-012-2299-1

D. Pauw, A. , D. Stoppa-lyonnet, N. Andrieu, and E. B. Asselain, « [Estimation of individual breast cancer risk: relevance and limits of risk estimation models] », Bulletin Du Cancer, vol.96, issue.10, 2009.

S. M. Domchek, M. Tara, S. L. Friebel, T. Neuhausen, G. Wagner et al., Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study, The Lancet Oncology, vol.7, issue.3, pp.223-252, 2006.
DOI : 10.1016/S1470-2045(06)70585-X

J. A. Dongen, A. C. Van, I. S. Voogd, C. Fentiman, R. J. Legrand et al., « Long-Term Results of a Randomized Trial Comparing Breast-Conserving Therapy With Mastectomy: European Organization for Research and Treatment of Cancer 10801 Trial », Journal of the National Cancer Institute, vol.92, issue.14, 2000.

J. C. Drooger, J. Maartje, C. M. Hooning, . Seynaeve, H. A. Margreet et al., Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature, Cancer Treatment Reviews, vol.41, issue.2, 2015.
DOI : 10.1016/j.ctrv.2014.12.002

C. Early-breast, . Trialists-'collaborative, . Group, and . Ebctcg-), « Polychemotherapy for Early Breast Cancer: An Overview of the Randomised Trials. Early Breast Cancer Trialists' Collaborative Group, Lancet, issue.9132, pp.352-930, 1998.

D. F. Easton, D. T. Bishop, D. Ford, and G. P. Crockford, « Genetic Linkage Analysis in Familial Breast and Ovarian Cancer: Results from 214 Families. The Breast Cancer Linkage Consortium, American Journal of Human Genetics, vol.52, issue.4, pp.678-701, 1993.

H. Eerola, P. Heikkilä, A. Tamminen, K. Aittomäki, C. Blomqvist et al., Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families, Breast Cancer Research, vol.92, issue.1, pp.10-1186, 2005.
DOI : 10.1002/1097-0142(20010701)92:1<37::AID-CNCR1289>3.0.CO;2-F

A. Eisen, G. G. Fletcher, S. Gandhi, M. Mates, O. C. Freedman et al., Optimal systemic therapy for early breast cancer in women: a clinical practice guideline, Current Oncology, vol.22, issue.0, 2015.
DOI : 10.3747/co.22.2320

A. Eisen, J. L. Klijn, P. Moller, H. T. Lynch, K. Offit et al., Mutation Carriers: An International Case-Control Study, Journal of Clinical Oncology, vol.23, issue.30, 2005.
DOI : 10.1200/JCO.2004.00.7138

F. Eisinger, N. Alby, A. Bremond, J. Dauplat, M. Espié et al., « Recommendations for Medical Management of Hereditary Breast and Ovarian Cancer: The French National Ad Hoc Committee, Annals of Oncology, vol.9, issue.9, pp.939-50, 1998.
DOI : 10.1023/A:1008389021382

F. Eisinger, B. Bressac, D. Castaigne, P. Cottu, J. Lansac et al., « [Identification and management of hereditary breast-ovarian cancers, Pathologie-Biologie, vol.54, issue.4, 2004.

C. W. Elston, I. O. Et, and . Ellis, pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.9, issue.5, 1991.
DOI : 10.1016/0277-5379(88)90171-X

H. Farmer, N. Mccabe, C. J. Lord, A. N. Tutt, D. A. Johnson et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.11, issue.7035, 2005.
DOI : 10.1177/1087057103008003013

A. Finch, M. B. Lubinski, H. T. Lynch, B. Moller, J. Rosen et al., Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women with a BRCA1 or BRCA2 Mutation, Obstetrical & Gynecological Survey, vol.62, issue.1, 2006.
DOI : 10.1097/01.ogx.0000251480.69322.50

C. Fischer, K. Kuchenbäcker, C. Engel, S. Zachariae, K. Rhiem et al., mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium, Journal of Medical Genetics, vol.12, issue.6, pp.360-67, 2013.
DOI : 10.1136/jmedgenet-2012-101415

F. H. Fodor, A. Weston, I. J. Bleiweiss, L. D. Mccurdy, M. M. Walsh et al., Frequency and Carrier Risk Associated with Common BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Breast Cancer Patients, Frequency and Carrier Risk Associated with Common BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Breast Cancer Patients, pp.45-51, 1998.
DOI : 10.1086/301903

W. D. Foulkes, K. Metcalfe, P. Sun, W. M. Hanna, H. T. Lynch et al., Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer: The Influence of Age, Grade, and Histological Type, Clinical Cancer Research, vol.10, issue.6, pp.2029-2063, 2004.
DOI : 10.1158/1078-0432.CCR-03-1061

M. H. Frost, L. Tanya, L. C. Hoskin, A. C. Hartmann, J. L. Degnim et al., Contralateral Prophylactic Mastectomy: Long-Term Consistency of Satisfaction and Adverse Effects and the Significance of Informed Decision-Making, Quality of Life, and Personality Traits, Annals of Surgical Oncology, vol.6, issue.11, pp.3110-3126, 2011.
DOI : 10.1245/s10434-011-1917-7

M. Golshan, A. Miron, A. J. Nixon, J. E. Garber, E. P. Cash et al., The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy, The American Journal of Surgery, vol.192, issue.1, 2006.
DOI : 10.1016/j.amjsurg.2005.12.005

P. J. Goodwin, . Kelly-anne, D. W. Phillips, M. West, J. L. Ennis et al., Mutation Carriers: An International Prospective Breast Cancer Family Registry Population-Based Cohort Study, Journal of Clinical Oncology, vol.30, issue.1, 2012.
DOI : 10.1200/JCO.2010.33.0068

S. Gourgou-bourgade, D. Cameron, P. Poortmans, B. Asselain, D. Azria et al., « Guidelines for Time-to-Event End Point Definitions in Breast Cancer Trials: Results of the DATECAN Initiative (Definition for the Assessment of Time-to-Event Endpoints in CANcer Trials), Annals of Oncology, vol.26, issue.5, 2015.

M. K. Graeser, C. Engel, K. Rhiem, D. Gadzicki, U. Bick et al., Mutation Carriers, Journal of Clinical Oncology, vol.27, issue.35, 2009.
DOI : 10.1200/JCO.2008.19.9430

J. Gronwald, A. Robidoux, C. Kim-sing, N. Tung, H. T. Lynch et al., Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, Breast Cancer Research and Treatment, vol.22, issue.2, pp.421-448, 2014.
DOI : 10.1007/s10549-014-3026-3

B. G. Haffty, E. Harrold, J. Atif, P. Khan, . Pathare et al., Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status, The Lancet, vol.359, issue.9316, pp.1471-77, 2002.
DOI : 10.1016/S0140-6736(02)08434-9

J. M. Hall, M. K. Lee, B. Newman, J. E. Morrow, L. A. Anderson et al., Linkage of early-onset familial breast cancer to chromosome 17q21, Science, vol.250, issue.4988, pp.250-1684, 1990.
DOI : 10.1126/science.2270482

L. C. Hartmann, D. J. Schaid, J. E. Woods, T. P. Crotty, J. L. Myers et al., Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer, New England Journal of Medicine, vol.340, issue.2, pp.77-84, 1999.
DOI : 10.1056/NEJM199901143400201

H. , G. Jeanblanc, O. Scemama, and E. R. Vaissière, « Dépistage du cancer du sein en France: identification des femmes à haut risque et modalités de dépistage-Synthèse, 2014.

B. A. Heemskerk-gerritsen, T. M. Cecile, M. B. Brekelmans, A. N. Menke-pluymers, M. M. Van-geel et al., Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic, Prophylactic Mastectomy in BRCA1, 2007.

A. Y. Ho, G. Gupta, T. A. King, C. A. Perez, S. M. Patil et al., Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy, Cancer, vol.115, issue.15 pt 1, 2012.
DOI : 10.1002/cncr.27480

E. Honrado, J. Benítez, and J. Palacios, Histopathology of BRCA1- and BRCA2-associated breast cancer, Critical Reviews in Oncology/Hematology, vol.59, issue.1, 2006.
DOI : 10.1016/j.critrevonc.2006.01.006

C. A. Hudis, E. William, J. P. Barlow, R. J. Costantino, K. I. Gray et al., Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System, Journal of Clinical Oncology, vol.25, issue.15, 2007.
DOI : 10.1200/JCO.2006.10.3523

T. Huzarski, T. Byrski, J. Gronwald, B. Górski, P. Domagala et al., -Positive Breast Cancer, Journal of Clinical Oncology, vol.31, issue.26, 2013.
DOI : 10.1200/JCO.2012.45.3571

URL : https://hal.archives-ouvertes.fr/hal-00837832

J. Jobsen, J. Van-der-palen, S. Riemersma, H. Heijmans, F. Ong et al., Pattern of Ipsilateral Breast Tumor Recurrence After Breast-Conserving Therapy, International Journal of Radiation Oncology*Biology*Physics, vol.89, issue.5, 2014.
DOI : 10.1016/j.ijrobp.2014.04.039

J. J. Jobsen, J. Van-der-palen, and J. H. Meerwaldt, The impact of age on local control in women with pT1 breast cancer treated with conservative surgery and radiation therapy, European Journal of Cancer, vol.37, issue.15, pp.37-1820, 1990.
DOI : 10.1016/S0959-8049(01)00173-3

O. T. Jóhannsson, I. Idvall, C. Anderson, A. Borg, R. B. Barkardóttir et al., Tumour biological features of BRCA1-induced breast and ovarian cancer, European Journal of Cancer, vol.33, issue.3, pp.362-71, 1990.
DOI : 10.1016/S0959-8049(97)89007-7

R. Kaas, S. Verhoef, J. Wesseling, M. A. Rookus, S. A. Hester et al., Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers, Annals of Surgery, vol.251, issue.3, pp.488-92, 2010.
DOI : 10.1097/SLA.0b013e3181c3c36d

S. E. Karp, P. N. Tonin, L. R. Bégin, J. J. Martinez, J. C. Zhang et al., Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women, Influence of BRCA1 Mutations on Nuclear Grade and Estrogen Receptor Status of Breast Carcinoma in Ashkenazi Jewish Women, pp.435-476, 1997.
DOI : 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y

N. D. Kauff, M. Susan, T. M. Domchek, M. E. Friebel, J. Robson et al., Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study, Journal of Clinical Oncology, vol.26, issue.8, 2008.
DOI : 10.1200/JCO.2007.13.9626

M. King, J. H. Marks, and J. B. , Mandell, et New York Breast Cancer Study Group « Breast and Ovarian Cancer Risks due to Inherited Mutations in BRCA1 and BRCA2, Science, vol.302, issue.5645, 2003.

Y. M. Kirova, A. Savignoni, B. Sigal-zafrani, A. De-la-rochefordiere, J. Rémy et al., « Is the Breast-Conserving Treatment with Radiotherapy Appropriate in BRCA1/2 Mutation Carriers? Long-Term Results and Review of the Literature, Breast Cancer Research and Treatment, vol.120, issue.1, pp.10-1007, 2010.

Y. M. Kirova, D. Stoppa-lyonnet, A. Savignoni, B. Sigal-zafrani, and N. Fabre, Alain Fourquet, et Institut Curie Breast Cancer Study Group « Risk of Breast Cancer Recurrence and Contralateral Breast Cancer in Relation to BRCA1 and BRCA2 Mutation Status Following Breast-Conserving Surgery and Radiotherapy », European Journal of Cancer, issue.15, p.41, 1990.

Y. Komoike, F. Akiyama, Y. Iino, T. Ikeda, S. Akashi-tanaka et al., Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer, Cancer, vol.18, issue.1, 2006.
DOI : 10.1002/cncr.21551

S. Koslow, L. A. Pharmer, A. M. Scott, M. Stempel, M. Morrow et al., Long-Term Patient-Reported Satisfaction after Contralateral Prophylactic Mastectomy and Implant Reconstruction, Annals of Surgical Oncology, vol.19, issue.11, pp.3422-3451, 2013.
DOI : 10.1245/s10434-013-3026-2

S. R. Lakhani, J. Jacquemier, J. P. Sloane, B. A. Gusterson, T. J. Anderson et al., Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations, Multifactorial Analysis of Differences between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations, pp.1138-1183, 1998.
DOI : 10.1093/jnci/90.15.1138

S. R. Lakhani, J. Marc, J. Van-de-vijver, T. J. Jacquemier, P. P. Anderson et al., et for the Breast Cancer Linkage Consortium « The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2 », Journal of Clinical Oncology, vol.20, issue.9, 2002.

. Lee, W. Han-byoel, and . Han, Unique Features of Young Age Breast Cancer and Its Management, Journal of Breast Cancer, vol.17, issue.4, 2014.
DOI : 10.4048/jbc.2014.17.4.301

L. J. Lee, B. Alexander, S. J. Schnitt, A. Comander, B. Gallagher et al., Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers, Cancer, vol.376, issue.suppl; abstr 50, 2011.
DOI : 10.1002/cncr.25911

R. Lidereau, F. Eisinger, M. Champème, C. Noguès, I. Bièche et al., « Major Improvement in the Efficacy of BRCA1 Mutation Screening Using Morphoclinical Features of Breast Cancer, Cancer Research, vol.60, issue.5, pp.1206-1216, 2000.

F. Liebens, B. Patricia, A. Carly, S. Pastijn, and . Rozenberg, « Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in, European Journal of Cancer, vol.43, issue.2, 2006.

L. Lostumbo, N. E. Carbine, and J. Wallace, « Prophylactic Mastectomy for the Prevention of Breast Cancer ». The Cochrane Database of Systematic Reviews, 2010.

B. J. Lynch, A. Joseph, S. S. Holden, S. L. Buys, D. K. Neuhausen et al., Pathobiologic characteristics of hereditary breast cancer, Pathobiologic Characteristics of Hereditary Breast Cancer, pp.1140-1184, 1998.
DOI : 10.1016/S0046-8177(98)90427-0

K. Malone, J. Daling, J. Thompson, O. Brien, C. Francisco et al., BRCA1 Mutations and Breast Cancer in the General Population, JAMA, vol.279, issue.12, 1998.
DOI : 10.1001/jama.279.12.922

L. Mauriac, M. Durand, A. Avril, and J. M. Dilhuydy, « Effects of Primary Chemotherapy in Conservative Treatment of Breast Cancer Patients with Operable Tumors Larger than 3 Cm. Results of a Randomized Trial in a Single Centre, Annals of Oncology: Official Journal of the European Society for Medical Oncology, vol.2, issue.5, pp.347-54, 1991.

N. Mavaddat, S. Peock, D. Frost, S. Ellis, R. Platte et al., Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE, JNCI Journal of the National Cancer Institute, vol.105, issue.11, 2013.
DOI : 10.1093/jnci/djt095

E. Mazzola, A. Blackford, G. Parmigiani, and S. Biswas, Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO, Cancer Informatics, vol.14, issue.2, pp.147-57, 2015.
DOI : 10.4137/CIN.S17292

H. Meijers-heijboer, B. Van-geel, W. L. Van-putten, S. C. Henzen-logmans, C. Seynaeve et al., Mutation, Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation, pp.159-64, 2001.
DOI : 10.1056/NEJM200107193450301

URL : https://hal.archives-ouvertes.fr/hal-00837832

T. S. Menes, M. B. Terry, D. Goldgar, I. L. Andrulis, J. A. Knight et al., Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry, Breast Cancer Research and Treatment, vol.106, issue.6, 2015.
DOI : 10.1007/s10549-015-3419-y

K. A. Metcalfe, D. Birenbaum-carmeli, J. Lubinski, J. Gronwald, H. Lynch et al., International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers, International Journal of Cancer, vol.94, issue.9, 2008.
DOI : 10.1002/ijc.23340

K. A. Metcalfe, J. Lubinski, P. Ghadirian, H. Lynch, C. Kim-sing et al., Mutation: The Hereditary Breast Cancer Clinical Study Group, Journal of Clinical Oncology, vol.26, issue.7, 2008.
DOI : 10.1200/JCO.2007.12.6078

K. Metcalfe, J. Lubinski, H. T. Lynch, P. Ghadirian, W. D. Foulkes et al., Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations, JNCI Journal of the National Cancer Institute, vol.102, issue.24, 2010.
DOI : 10.1093/jnci/djq443

K. Metcalfe, H. T. Lynch, P. Ghadirian, N. Tung, C. Kim-sing et al., Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers, Breast Cancer Research and Treatment, vol.25, issue.1, pp.287-96, 2011.
DOI : 10.1007/s10549-010-1336-7

K. Metcalfe, H. T. Lynch, P. Ghadirian, N. Tung, I. Olivotto et al., Mutation Carriers, Journal of Clinical Oncology, vol.22, issue.12, 2004.
DOI : 10.1200/JCO.2004.04.033

Y. Miki, J. Swensen, D. Shattuck-eidens, P. A. Futreal, K. Harshman et al., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, vol.266, issue.5182, pp.266-66, 1994.
DOI : 10.1126/science.7545954

A. Moran, C. O-'hara, S. Khan, L. Shack, E. Woodward et al., Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations, Risk of Cancer Other than Breast or Ovarian in Individuals with BRCA1 and BRCA2 Mutations, pp.235-277, 2012.
DOI : 10.1007/s10689-011-9506-2

A. Muendlein, B. H. Rohde, K. Gasser, A. Haid, S. Rauch et al., Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer, Journal of Cancer Research and Clinical Oncology, vol.150, issue.Suppl 6, pp.432-447, 2015.
DOI : 10.1007/s00432-015-1986-2

S. A. Narod, . Brunet, . Ghadirian, . Robson, S. Heimdal et al., Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study, The Lancet, vol.356, issue.9245, pp.1876-81, 2000.
DOI : 10.1016/S0140-6736(00)03258-X

S. A. Narod, N. Tung, J. Lubinski, T. Huzarski, M. Robson et al., A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers, Current Oncology, vol.21, issue.2, pp.64-68, 2014.
DOI : 10.3747/co.21.1656

S. A. Narod, K. Metcalfe, H. T. Lynch, P. Ghadirian, A. Robidoux et al., Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?, Breast Cancer Research and Treatment, vol.29, issue.1, pp.273-79, 2013.
DOI : 10.1007/s10549-013-2429-x

M. P. Nilsson, L. Hartman, I. Idvall, U. Kristoffersson, O. T. Johannsson et al., Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status, Breast Cancer Research and Treatment, vol.376, issue.9737, pp.10-1007, 2014.
DOI : 10.1007/s10549-014-2842-9

S. Noguchi, T. Kasugai, Y. Miki, T. Fukutomi, M. Emi et al., Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women, Cancer, vol.16, issue.10, pp.2200-2205, 1999.
DOI : 10.1002/(SICI)1097-0142(19990515)85:10<2200::AID-CNCR14>3.0.CO;2-S

J. Palacios, E. Honrado, A. Osorio, A. Cazorla, D. Sarrió et al., « Immunohistochemical Characteristics Defined by Tissue Microarray of Hereditary Breast Cancer Not Attributable to BRCA1 or BRCA2 Mutations Differences from Breast Carcinomas Arising in BRCA1 and BRCA2 Mutation Carriers », Clinical Cancer Research, vol.9, issue.10, pp.3606-3620, 2003.

G. Parmigiani, D. Berry, and O. Aguilar, Determining Carrier Probabilities for Breast Cancer???Susceptibility Genes BRCA1 and BRCA2, The American Journal of Human Genetics, vol.62, issue.1, pp.145-58, 1998.
DOI : 10.1086/301670

K. Phillips, R. L. Milne, M. A. Rookus, M. B. Daly, A. C. Antoniou et al., Mutation Carriers, Journal of Clinical Oncology, vol.31, issue.25, 2013.
DOI : 10.1200/JCO.2012.47.8313

L. J. Pierce, M. Strawderman, S. A. Narod, I. Oliviotto, A. Eisen et al., Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations, Effect of Radiotherapy after Breast-Conserving Treatment in Women with Breast Cancer and Germline BRCA1/2 Mutations, pp.3360-69, 2000.
DOI : 10.1200/JCO.2000.18.19.3360

L. J. Pierce, . Kelly-anne, K. A. Phillips, S. Griffith, D. K. Buys et al., Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy, Breast Cancer Research and Treatment, vol.41, issue.2, 2010.
DOI : 10.1007/s10549-010-0894-z

T. R. Rebbeck, T. Friebel, H. T. Lynch, S. L. Neuhausen, L. Van-'t-veer et al., Mutation Carriers: The PROSE Study Group, Journal of Clinical Oncology, vol.22, issue.6, 2004.
DOI : 10.1200/JCO.2004.04.188

T. R. Rebbeck, T. Friebel, T. Wagner, H. T. Lynch, J. E. Garber et al., Mutation Carriers: The PROSE Study Group, Journal of Clinical Oncology, vol.23, issue.31, 2005.
DOI : 10.1200/JCO.2004.00.8151

T. R. Rebbeck, T. Henry, S. L. Lynch, S. A. Neuhausen, L. Narod et al., Mutations, Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations, pp.1616-1638, 2002.
DOI : 10.1056/NEJMoa012158

T. R. Rebbeck, A. M. Levin, A. Eisen, C. Snyder, P. Watson et al., Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers, Breast Cancer Risk after Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers, pp.1475-79, 1999.
DOI : 10.1093/jnci/91.17.1475

G. Rennert, S. Bisland-naggan, O. Barnett-griness, N. Bar-joseph, S. Zhang et al., Mutations, New England Journal of Medicine, vol.357, issue.2, pp.115-138, 2007.
DOI : 10.1056/NEJMoa070608

L. Robertson, H. Hanson, S. Seal, M. Warren-perry, D. Hughes et al., BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years, British Journal of Cancer, vol.21, issue.6, 2012.
DOI : 10.1186/1471-2407-9-86

M. E. Robson, O. Pierre, J. Chappuis, N. Satagopan, J. Wong et al., A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment, Breast Cancer Research, vol.20, issue.2, pp.8-17, 2004.
DOI : 10.1200/JCO.20.6.1480

M. Robson, D. Levin, M. Federici, J. Satagopan, F. Bogolminy et al., Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations, JNCI: Journal of the National Cancer Institute, vol.91, issue.24, 1999.
DOI : 10.1093/jnci/91.24.2112

M. D. Schwartz, C. Lerman, B. Brogan, B. N. Peshkin, C. Hughes-halbert et al., Counseling and Testing on Newly Diagnosed Breast Cancer Patients, Journal of Clinical Oncology, vol.22, issue.10, 2004.
DOI : 10.1200/JCO.2004.04.086

C. Seynaeve, L. C. Verhoog, L. M. Van-de-bosch, A. N. Van-geel, M. Menke-pluymers et al., Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy, European Journal of Cancer, vol.40, issue.8, 1990.
DOI : 10.1016/j.ejca.2004.01.017

S. Shanley, K. Mcreynolds, A. Ardern-jones, R. Ahern, I. Fernando et al., Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom, Clinical Cancer Research, vol.12, issue.23, 2006.
DOI : 10.1158/1078-0432.CCR-06-1244

A. J. Stolier and R. L. Corsetti, « Newly Diagnosed Breast Cancer Patients Choose Bilateral Mastectomy over Breast-Conserving Surgery When Testing Positive for a BRCA1/2 Mutation, The American Surgeon, vol.71, issue.12, pp.1031-1064, 2005.

M. R. Stratton, D. Ford, S. Neuhasen, S. Seal, R. Wooster et al., Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q, Nature Genetics, vol.1, issue.1, pp.10-0594, 1038.
DOI : 10.1038/ng1093-109

N. Tung, Y. Wang, L. C. Collins, J. Kaplan, H. Li et al., Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features, Breast Cancer Research, vol.27, issue.1, pp.10-1186, 2010.
DOI : 10.1200/JCO.2008.21.7695

A. Tutt, M. Robson, J. E. Garber, S. M. Domchek, M. W. Audeh et al., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial, The Lancet, vol.376, issue.9737, pp.37610-1016, 2010.
DOI : 10.1016/S0140-6736(10)60892-6

A. Valachis, A. D. Nearchou, and P. Lind, Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis, Breast Cancer Research and Treatment, vol.101, issue.15 suppl, pp.443-55, 2014.
DOI : 10.1007/s10549-014-2890-1

. Van-der-noll, S. Ruud, N. Marchetti, J. H. Steeghs, M. W. Beijnen et al., Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer, British Journal of Cancer, vol.61, issue.3, 2015.
DOI : 10.1038/bjc.2015.256

T. C. Van-sprundel, M. Schmidt, M. Rookus, C. J. Brohet, E. Van-asperen et al., Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers, British Journal of Cancer, vol.351, issue.3, 2005.
DOI : 10.1038/sj.bjc.6602703

L. Verhoog, C. Brekelmans, . Seynaeve, . Lmc-van-den-bosch, A. Dahmen et al., « Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1, The Lancet, vol.35197, issue.9099, pp.316-337, 1998.

C. Villarreal-garza, J. N. Weitzel, M. Llacuachaqui, E. Sifuentes, M. C. Magallanes-hoyos et al., The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer, Breast Cancer Research and Treatment, vol.348, issue.5, pp.389-94, 2015.
DOI : 10.1007/s10549-015-3312-8

E. Warner, W. Foulkes, P. Goodwin, W. Meschino, J. Blondal et al., Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer, Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women with Breast Cancer, pp.1241-1288, 1999.
DOI : 10.1093/jnci/91.14.1241

E. Wasteson, K. Sandelin, Y. Brandberg, M. Wickman, and E. B. Arver, High satisfaction rate ten years after bilateral prophylactic mastectomy - a longitudinal study, European Journal of Cancer Care, vol.7, issue.4, 2011.
DOI : 10.1111/j.1365-2354.2010.01204.x

R. Wooster, S. L. Neuhausen, J. Mangion, Y. Quirk, D. Ford et al., Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13, Science, vol.265, issue.5181, pp.265-2088, 1994.
DOI : 10.1126/science.8091231

S. Zhang, R. Royer, S. Li, J. R. Mclaughlin, B. Rosen et al., Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer, Gynecologic Oncology, vol.121, issue.2, 2011.
DOI : 10.1016/j.ygyno.2011.01.020

. Le-risque-de-récidive-locale-dans-le-sein-traité, qui peut influencer le choix de la prise en charge controlatérale) n'est pas très différent en cas de mutation BRCA1/2 et dans les formes sporadiques [86,91,92]. Le recul est cependant souvent limité à quelques années, la localisation de la récidive (dans le même quadrant ou non) est rarement signifiée et l'influence des traitements systémiques n'est pas prise en compte

. En-conclusion, augmentation du risque de cancer controlatéral, en cas de mutation BRCA, est acquise (niveau de preuve 2), le bénéfice éventuel sur la survie de la chirurgie préventive ou d'un diagnostic précoce du cancer controlatéral n'est pas documenté

. Enfin, ces études rétrospectives ne prennent pas en considération, du fait de la petite taille de l'échantillon, le gène en cause (BRCA1 ou BRCA2) qui n'est probablement pas

. Le, -la perception de la maladie à travers le vécu familial (nombre de cas de cancers du sein/ovaire, proximité des personnes touchées, nombre de décès par cancer dans la famille) -la présentation par les soignants des risques et des options
URL : https://hal.archives-ouvertes.fr/halshs-00408978

. Femme-porteuse-d, une mutation ayant un antécédent de cancer du sein traité Si les experts sont unanimes à recommander de faire le maximum pour identifier la mutation avant le diagnostic de cancer [109], de nombreuses patientes auront leur diagnostic de mutation en même temps ou après le cancer du sein. Actuellement, la consultation génétique, avec ses possibles retombées sur le traitement local

. Enfin and Z. Dans-une-revue-récente, étude s'intéressant spécifiquement aux suites et à la morbidité spécifique de la chirurgie prophylactique chez les patientes ayant déjà eu un cancer du sein Une seule étude [18] relève des taux de complications comparables après reconstruction chez des patientes indemnes ou ayant eu un cancer avec un taux global de complications et effets secondaires de 50 % dont 70 % avaient nécessité une réintervention. À noter dans cette étude, pour les complications précoces (infection, nécrose, saignement, luxation de prothèse), un taux d'infection plus élevé (26 vs 13 %) dans le groupe des patientes ayant déjà eu un cancer

B. Heemskerk-gerritsen, C. Brekelmans, and M. Menke-pluymers, Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic, Annals of Surgical Oncology, vol.98, issue.12, pp.3335-3379, 2007.
DOI : 10.1245/s10434-007-9449-x

S. Zakaria and A. Degnim, Prophylactic Mastectomy, Surgical Clinics of North America, vol.87, issue.2, pp.317-348, 2007.
DOI : 10.1016/j.suc.2007.01.009

K. Metcalfe, H. Lynch, and P. Ghadirian, Mutation Carriers, Journal of Clinical Oncology, vol.22, issue.12, pp.2328-2363, 2004.
DOI : 10.1200/JCO.2004.04.033

S. Lord, W. Lei, and P. Craft, A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer, European Journal of Cancer, vol.43, issue.13
DOI : 10.1016/j.ejca.2007.06.007

F. Liebens, C. B. Pastijn, A. Rozenberg, and S. , Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006, European Journal of Cancer, vol.43, issue.2, pp.238-57, 2007.
DOI : 10.1016/j.ejca.2006.07.019

L. Pierce, A. Levin, and T. Rebbeck, -Associated Stage I/II Breast Cancer, Journal of Clinical Oncology, vol.24, issue.16, pp.2437-2480, 2006.
DOI : 10.1200/JCO.2005.02.7888

URL : https://hal.archives-ouvertes.fr/lirmm-00109169

L. Verhoog, C. Brekelmans, C. Seynaeve, E. Meijers-heijboer, and J. Klijn, Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer, British Journal of Cancer, vol.83, issue.3, pp.384-390, 2000.
DOI : 10.1054/bjoc.2000.1239

K. Shahedi, M. Emanuelsson, F. Wiklund, and H. Gronberg, High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma, Cancer, vol.352, issue.6, pp.1237-1279, 2006.
DOI : 10.1002/cncr.21753

Y. Kirova, D. Stoppa-lyonnet, A. Savignoni, B. Sigal-zafrani, N. Fabre et al., Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy, European Journal of Cancer, vol.41, issue.15, pp.2304-2315, 2005.
DOI : 10.1016/j.ejca.2005.02.037

M. Robson, P. Chappuis, and J. Satagopan, A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment, Breast Cancer Research, vol.20, issue.2, pp.8-17, 2004.
DOI : 10.1200/JCO.20.6.1480

B. Haffty, E. Harrold, and A. Khan, Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status, The Lancet, vol.359, issue.9316, pp.1471-1478, 2002.
DOI : 10.1016/S0140-6736(02)08434-9

L. Lostumbo, N. Carbine, J. Wallace, and J. Ezzo, Prophylactic mastectomy for the prevention of breast cancer, Cochrane Database Syst Rev, p.2748, 2004.

G. Rennert, S. Bisland-naggan, and O. Barnett-griness, Mutations, New England Journal of Medicine, vol.357, issue.2, pp.115-138, 2007.
DOI : 10.1056/NEJMoa070608

M. Tilanus-linthorst, I. Obdeijn, and W. Hop, BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials, Clinical Cancer Research, vol.13, issue.24, pp.7357-62, 2007.
DOI : 10.1158/1078-0432.CCR-07-0689

G. Schwartz, K. Hughes, and H. Lynch, Proceedings of the International Consensus Conference on Breast Cancer Risk, Genetics, & Risk Management, April, 2007, Cancer, vol.113, issue.10, pp.2627-2664, 2007.
DOI : 10.1002/cncr.23903

J. Khatcheressian, A. Wolff, and T. Smith, American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting, Journal of Clinical Oncology, vol.24, issue.31, pp.5091-5098, 2006.
DOI : 10.1200/JCO.2006.08.8575

L. Herrinton, W. Barlow, and O. Yu, Efficacy of Prophylactic Mastectomy in Women With Unilateral Breast Cancer: A Cancer Research Network Project, Journal of Clinical Oncology, vol.23, issue.19, pp.4275-86, 2005.
DOI : 10.1200/JCO.2005.10.080